Plain-English translation of NCT06509945 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing allogeneic peripheral blood stem cell transplantation—a procedure where healthy stem cells from a matched donor are given to patients with aggressive T-cell lymphoma. The study focuses on patients whose cancer has shrunk or disappeared after their first round of chemotherapy. Researchers want to see if this transplant can prevent the cancer from coming back and improve survival.
T-cell lymphoma is a rare and aggressive blood cancer that is difficult to treat and often comes back even after initial chemotherapy. This trial exists to find out whether this transplant approach can help keep the cancer away longer and give patients better long-term outcomes than standard treatments alone.
If you join this trial, you will receive a conditioning treatment (chemotherapy and/or radiation) to prepare your body, followed by an infusion of stem cells from your matched donor on day 0. You will then have frequent follow-up visits: bone marrow tests at 2 weeks, 4 weeks, and then monthly for the first year and every 2 months in the second year. You will also have imaging scans every 6 months. The trial tracks you for at least 2 years to monitor how well the transplant is working, watch for side effects, and check whether your cancer stays away.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China